A hybrid Bayesian-frequentist predictive design for monitoring multi-stage clinical trials

References

• Berry, D. A. (1985). Interim Analyses in Clinical Trials: Classical vs. Bayesian Approaches, Statistics in Medicine 4: 521–526.
   PubMed Web of Science ®Google Scholar
• Brown, B. W., Heson, J., Atkinson, N., and Rozell, M. E. (1987). Projection from Previous Studies: A Bayesian and Frequentist Compromise, Controlled Clinical Trials 8: 29–44.
   PubMedGoogle Scholar
• Chang, M. (2008). Adaptive Design Theory and Implementation Using SAS and R, Boca Raton: Chapman & Hall.
   Google Scholar
• Chow, S. C., Corey, R., and Lin, M. (2012). On the Independence of Data Monitoring Committee in Adaptive Design Clinical Trials, Journal of Biopharmaceutical Statistics 22: 853–867.
   PubMed Web of Science ®Google Scholar
• Cox, D. R. (1999). Discussion of “Some Statistical Heresies” (Lindsey), Statistician 48 (part 1): 1–40.
   Google Scholar
• Djeridi, Z. and Merabet, H. (2016). Choice of the Prior in the Bayesian Design for the Clinical Trials, Sciences et Technologie A 44: 27–31.
   Google Scholar
• Everitt, B. and Pickles, A. (1999). Statistical Aspects of the Design and Analysis of Clinical Trials, London: Imperial College.
   Google Scholar
• Gajewski, B. J. and Mayo, M. S. (2006). Bayesian Sample Size Calculations in Phase II Clinical Trials Using a Mixture of Informative Priors, Statistics in Medicine 25: 2554–2566.
   PubMed Web of Science ®Google Scholar
• Gould, A. L. (1983). Abandoning Lost Causes (Early Termination of Unproductive Clinical Trials), Proceedings of Biopharmaceutical Section, Toronto: 31–34.
   Google Scholar
• Gould, A. L. (2005). Timing of Futility Analyses for Proof of Concept Trials, Statistics in Medicine 24: 1815–1835.
   PubMed Web of Science ®Google Scholar
• Grieve, A. P. (1991). Predictive Probability in Clinical Trials, Biometrics 47: 323–330.
   PubMed Web of Science ®Google Scholar
• Heitjan, D. F. (1997). Bayesian Interim Analysis of Phase II Cancer Clinical Trials, Statistics in Medicine 16: 1791–1802.
   PubMed Web of Science ®Google Scholar
• Herson, J. (1979). Predictive Probability Early Termination Plans for Phase II Clinical Trials, Biometrics 35: 775–783.
   PubMed Web of Science ®Google Scholar
• Jennison, C. and Turnbull, B. W. (2000). Group Sequential Method with Applications to Clinical Trials, New York: Chapman & Hall/CRC Press.
   Google Scholar
• Johns, D. and Andersen, J. S. (1999). Use of Predictive Probabilities in Phase II and Phase III Clinical Trials, Journal of Biopharmaceutical Statistics 9: 67–79.
   PubMedGoogle Scholar
• Lecoutre, B. (2001). A Bayesian Predictive Procedures for Designing and Monitoring Experiments, in Bayesian Methods with Applications to Science, Policy and Official Statistics Luxemburg, pp. 301–310.
   Google Scholar
• Lecoutre, B., Derzko, G., and Grouin, J. M. (1995). Bayesian Predictive Approach for Inference about Proportions, Statistics in Medicine 14: 1057–1063.
   PubMed Web of Science ®Google Scholar
• Lee, J. J. and Feng, L. (2005). Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions, Journal of Clinical Oncology 23: 4450–4457.
   PubMed Web of Science ®Google Scholar
• Lee, J. J. and Liu, D. D. (2008). A Predictive Probability Design for Phase II Cancer Clinical Trials, Clinical Trials 5: 93–106.
   PubMed Web of Science ®Google Scholar
• Mayo, M. S. and Gajewski, B. J. (2004). Bayesian Sample Size Calculations in Phase II Clinical Trials Using Informative Conjugate Priors, Contemporary Clinical Trials 25: 157–167.
   Google Scholar
• Merabet, H. and Labdaoui, A. (2015). Bayesian Prediction Using Two-Stages Design in Experimental Trials, Nature & Technologie A-Sciences Fondamentals et Engineering 12: 11–23.
   Google Scholar
• Merabet, H., Labdaoui, A., and Druilhet, P. (2017). Bayesian Prediction for Two-Stage Sequential Analysis in Clinical Trials, Communication in Statistics - Theory & Methods 46: 9807–9816.
   Web of Science ®Google Scholar
• Robert, C. P. (2007). Bayesian Choice: From Decision-Theoretic Foundations to Computational Implementation, New York: Springer.
   Google Scholar
• Saville, B. R., Connor, J. T., Ayers, G. D., and Alvarez, J. (2014). The Utility of Bayesian Predictive Probabilities for Interim Monitoring of Clinical Trials, Clinical Trials.
   PubMed Web of Science ®Google Scholar
• Schultz, J. R., Nichol, F. R., Elfring, G. L., and Weed, S. D. (1973). Multiplestage Procedures for Drug Screening, Biometrics 29: 293–300.
   PubMed Web of Science ®Google Scholar
• Shao, Y., Mukhi, V., and Goldberg, J. D. (2008). A Hybrid Bayesian–Frequentist Approach to Evaluate Clinical Trial Designs for Tests of Superiority and Non-Inferiority, Statistics in Medicine 27: 504–519.
   PubMed Web of Science ®Google Scholar
• Simon, R. (1989). Optimal Two-Stage Design for Phase II Clinical Trials, Controlled Clinical Trials 10: 1–10.
   PubMedGoogle Scholar
• Spiegelhalter, D. J., Abrams, K. R., and Myles, J. P. (2004). Approaches to Clinical Trials and Health-Care Evaluation, Chichester: Wiley.
   Google Scholar
• Spiegelhalter, D. J. and Freedman, L. S. (1986). A Predictive Approach to Selecting the Size of a Clinical Trial, Based on Subjective Clinical Opinion, Statistics in Medicine 5: 1–13.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Freedman, L. S., and Blackburn, P. R. (1986). Monitoring Clinical Trials: Conditional or Predictive Power? Contemporary Clinical Trials 7: 8–17.
   Google Scholar
• Spiegelhalter, D. J., Freedman, L. S., and Parmar, M. K. (1994). Bayesian Approaches to Randomized Trials, Journal of Royal Statistical Society, Series A 157: 357–416.
   Google Scholar
• Stangl, D. K. and Berry, D. A. (1998). Bayesian Statistics in Medicine: Where Are We and Where Should We Be Going? Indian Journal of Statistics 60: 176–195.
   Google Scholar
• Tan, S. B. and Machin, D. (2002). Bayesian Two-Stage Designs for Phase II Clinical Trials, Statistics in Medicine 21: 1991–2012.
   PubMed Web of Science ®Google Scholar
• Teramukai, S., Daimon, T., and Zohar, S. (2012). A Bayesian Predictive Sample Size Selection Design for Single-Arm Exploratory Clinical Trials, Statistics in Medecine.
   PubMed Web of Science ®Google Scholar
• Thall, P. F. and Simon, R. (1994a). A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials, Contemporary Clinical Trials 15: 463–481.
   Google Scholar
• Thall, P. F. and Simon, R. (1994b). Practical Bayesian Guidelines for Phase IIB Clinical Trials, Biometrics 50: 337–e49.
   PubMed Web of Science ®Google Scholar
• Yanagihara, K., Yoshimura, K., Niimi, M., Yasuda, H., Sasaki, T., Nishimura, T., Ishiguro, T., Matsumoto, S., Kitano, T., Kanai, M., et al. (2010). Phase II Study of S-1 and Docetaxel for Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Cancer Chemotherapy and Pharmacology 66: 913–918.
   PubMed Web of Science ®Google Scholar
• Zohar, S., Teramukai, S., and Zhou, Y. (2008). Bayesian Design and Conduct of Phase II Single-Arm Clinical Trials With Binary Outcomes: A Tutorial, Contemporary Clinical Trials 29: 608–616.
   PubMed Web of Science ®Google Scholar